CannabiNext

CannabiNext is NOT a finished consumer product with Supplement Facts. It is a B2B ingredient platform — a proprietary excipient system that can be applied to any cannabinoid (CBD, THC, CBG, CBN, etc.) to dramatically improve water solubility and bioavailability.

AVAILABLE FORMATS: Powder premix (for capsules, tablets, sachets) and Liquid premix (for beverages, tinctures, edibles). Both use GRAS excipients accepted by major global regulatory authorities.

THE PROBLEM IT SOLVES: Cannabinoids are hydrophobic (oil-soluble, not water-soluble). Regular CBD has water solubility of approximately 0.001 mg/mL. This means most orally consumed CBD passes through the GI tract without meaningful absorption. Oil-based products depend heavily on dietary fat for any absorption — creating the variability problem.

CANNABINEXT SOLUTION: Uses Micro Matrix Technology to create a self-emulsifying solid-state system. Upon contact with GI fluids, the matrix forms fine micelles that present cannabinoids in a bioavailable form regardless of fed/fasted state.

KEY METRICS: Water solubility ~57 mg/mL (vs regular CBD ~0.001 mg/mL = 57,000× improvement). Maximum cannabinoid concentration: 59,000 mg/L (vs leading competitor 9,000–11,000 mg/L, vs regular CBD 15 mg/L). Neutral taste profile suitable for beverages. GRAS excipients. Patent-protected.

CannabiNext IS Micro Matrix Technology applied to cannabinoids. Understanding the platform means understanding the technology at its deepest level.

FORMULATION SCIENCE: The CannabiNext matrix consists of: (1) A high-HLB nonionic surfactant system (polysorbate family) that creates spontaneous emulsification. (2) A polysaccharide carrier (maltodextrin) that provides the solid-state matrix structure. (3) Organic acid and lipid components (stearic acid) that modulate release kinetics. (4) A silica derivative that prevents particle aggregation and ensures flowability.

SELF-EMULSIFYING MECHANISM: When the CannabiNext matrix contacts aqueous GI fluids, the surfactant system spontaneously forms micelles — tiny lipid spheres (typically <100 nm) with cannabinoid molecules trapped inside. These micelles are small enough to cross the unstirred water layer at the intestinal epithelium and present cannabinoids directly to absorptive enterocytes.

WHY SOLID-STATE MATTERS: Liquid CBD emulsions (nano-emulsions) are thermodynamically unstable — they separate over time, require cold storage, and have limited shelf life. CannabiNext's solid-state matrix is thermodynamically stable with 3+ year shelf life at room temperature. The emulsification happens IN VIVO (inside the body), not in the bottle.

MANUFACTURING ADVANTAGE: The powder premix format means manufacturers can use standard capsule/tablet/sachet equipment. No specialised nano-emulsion machinery required. Lower COGS. Easier quality control. Scalable from pilot to commercial volumes.

Key takeaway: CannabiNext is the underlying technology platform. CBDNext Supra Capsule is one finished product built on this platform. The platform can be licensed to manufacturers worldwide for any cannabinoid application.

CANNABINEXT NEUTRON (First Generation): Achieved 32× higher blood concentration vs regular CBD. Cmax: 486 ng/mL vs 15 ng/mL for regular CBD. AUC: 1,615 vs 58 h·ng/mL. Tmax: 0.50 hours for both (rapid absorption maintained). This was the proof-of-concept generation.

CANNABINEXT SUPRA (Second Generation — Current): Achieved 88× higher blood concentration vs regular CBD and approximately 3× higher than vaping/smoking. Supra Liquid: Cmax 1,336 ng/mL, Tmax 0.083 h (5 minutes!), AUC 2,227 h·ng/mL. Supra Powder: Cmax 1,560 ng/mL, Tmax 0.083 h (5 minutes!), AUC 4,662 h·ng/mL.

GENERATION COMPARISON: Neutron → Supra represents a ~3× improvement in Cmax (486 → 1,560 ng/mL) and ~3× improvement in AUC (1,615 → 4,662 h·ng/mL). This demonstrates the iterative R&D process — hundreds of formulation iterations to optimise the matrix composition.

WATER SOLUBILITY COMPARISON: CannabiNext ~57 mg/mL vs Leading Competitor ~10 mg/mL vs Cyclodextrin Complex ~2 mg/mL vs Regular CBD ~0.001 mg/mL. Maximum cannabinoid concentration: CannabiNext 59,000 mg/L vs Competitor 9,000–11,000 mg/L vs Regular CBD 15 mg/L.

CRITICAL CONTEXT: These are PRECLINICAL (animal) pharmacokinetic studies. The 88× figure comes from preclinical data. The HUMAN clinical data (CBDNext Supra Capsule study) showed 5.7× Cmax improvement — still exceptional, but different from the preclinical figure. Always specify which dataset you are referencing.

WHY THE DIFFERENCE: Preclinical-to-human translation typically shows lower fold-improvements due to species differences in GI physiology, metabolism, and absorption. A 5.7× human result from an 88× preclinical result is actually a strong translation ratio.

TARGET CUSTOMERS: CBD/cannabis product manufacturers, beverage companies entering the cannabinoid space, pharmaceutical companies developing cannabinoid therapeutics, white-label supplement manufacturers.

VALUE PROPOSITION: (1) Dramatically higher bioavailability = lower CBD dose required = lower raw material cost per effective dose. (2) Consistent absorption = predictable consumer experience = better reviews and repeat purchases. (3) Water solubility = beverage-compatible = access to the fastest-growing CBD product category. (4) Neutral taste = no 'hemp' flavour masking required. (5) Solid-state stability = 3+ year shelf life = reduced waste and returns.

COMPETITIVE LANDSCAPE: Most competing 'enhanced CBD' technologies use: Nano-emulsions (unstable, require cold chain, limited shelf life). Liposomes (expensive, variable quality, scaling challenges). Cyclodextrin complexes (limited solubility improvement, taste issues). Self-emulsifying drug delivery systems (SEDDS) — closest competitor but typically liquid-only. CannabiNext is unique in offering SOLID-STATE self-emulsification with the highest published concentration metrics.

LICENSING MODEL: Available for exclusive or non-exclusive territory licensing. Manufacturer receives the premix (powder or liquid) and incorporates into their finished product. MN Nutra provides: formulation support, stability data, regulatory dossier support, and marketing claims substantiation.

Key takeaway: Position CannabiNext as the technology that makes CBD products actually work consistently. The published human study on CBDNext Supra is the proof — show manufacturers that data and explain how the same platform can be applied to their product line.

APPROVED CLAIMS FOR B2B CONTEXT: 'Proprietary cannabinoid delivery platform with 57 mg/mL water solubility' | 'Preclinical data showing up to 88× blood concentration improvement' | 'Published human PK study on finished capsule product (5.7× Cmax)' | 'Available as powder or liquid premix for diverse product formats' | 'GRAS excipients accepted by major regulatory authorities' | 'Patent-protected composition' | 'Neutral taste suitable for beverages'

PROHIBITED CLAIMS: 'Treats any disease or condition' | 'FDA approved' | '88× bioavailability in humans' (this is preclinical data — must specify) | 'Guaranteed therapeutic effect' | 'Medical-grade' | 'Replaces pharmaceutical cannabis' | 'Cures pain/anxiety/insomnia'

REGULATORY LANDSCAPE: CBD regulatory status varies by country. CannabiNext as a delivery technology is regulatory-agnostic — it enhances whatever cannabinoid the manufacturer chooses to use. The GRAS excipient status simplifies regulatory pathways in most jurisdictions. Patent protection provides exclusivity for licensees.

IMPORTANT DISTINCTION FOR AFFILIATES: When speaking to DISTRIBUTORS about consumer products, reference the published human study (5.7× Cmax). When speaking to B2B INGREDIENT BUYERS/MANUFACTURERS, you may reference the full preclinical dataset (up to 88×) with appropriate caveats about preclinical vs human data.

Required FDA Disclaimer: 'These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.'